Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 304

1.

Effect of teriparatide on bone mineral density and fracture in postmenopausal osteoporosis: meta-analysis of randomised controlled trials.

Han SL, Wan SL.

Int J Clin Pract. 2012 Feb;66(2):199-209. doi: 10.1111/j.1742-1241.2011.02837.x. Review.

PMID:
22257045
2.
3.

Strontium ranelate for preventing and treating postmenopausal osteoporosis.

O'Donnell S, Cranney A, Wells GA, Adachi JD, Reginster JY.

Cochrane Database Syst Rev. 2006 Jul 19;(3):CD005326. Review. Update in: Cochrane Database Syst Rev. 2006;(4):CD005326.

PMID:
16856092
4.

Response rate of bone mineral density to teriparatide in postmenopausal women with osteoporosis.

Gallagher JC, Rosen CJ, Chen P, Misurski DA, Marcus R.

Bone. 2006 Dec;39(6):1268-75. Epub 2006 Aug 1.

PMID:
16884968
5.

A comparison of teriparatide and calcitonin therapy in postmenopausal Asian women with osteoporosis: a 6-month study.

Kung AW, Pasion EG, Sofiyan M, Lau EM, Tay BK, Lam KS, Wilawan K, Ongphiphadhanakul B, Thiebaud D.

Curr Med Res Opin. 2006 May;22(5):929-37.

PMID:
16709314
6.

Fracture risk reduction during treatment with teriparatide is independent of pretreatment bone turnover.

Delmas PD, Licata AA, Reginster JY, Crans GG, Chen P, Misurski DA, Wagman RB, Mitlak BH.

Bone. 2006 Aug;39(2):237-43. Epub 2006 Mar 24.

PMID:
16563890
7.

Strontium: new drug. Postmenopausal osteoporosis: too many unknowns.

[No authors listed]

Prescrire Int. 2005 Dec;14(80):207-11.

PMID:
16397977
8.

WITHDRAWN: Risedronate for the prevention and treatment of postmenopausal osteoporosis.

Cranney A, Adachi JD, Guyatt G, Papaioannou A, Robinson VA, Shea BJ, Tugwell P, Waldegger LM, Weaver B, Wells G, Zytaruk N.

Cochrane Database Syst Rev. 2007 Jul 18;(1):CD004523. Review. Update in: Cochrane Database Syst Rev. 2008;(1):CD004523.

PMID:
17636764
9.

Risedronate for the prevention and treatment of postmenopausal osteoporosis.

Cranney A, Waldegger L, Zytaruk N, Shea B, Weaver B, Papaioannou A, Robinson V, Wells G, Tugwell P, Adachi JD, Guyatt G.

Cochrane Database Syst Rev. 2003;(4):CD004523. Review. Update in: Cochrane Database Syst Rev. 2006;(1):CD004523.

PMID:
14584020
10.

Safety and efficacy of teriparatide in elderly women with established osteoporosis: bone anabolic therapy from a geriatric perspective.

Boonen S, Marin F, Mellstrom D, Xie L, Desaiah D, Krege JH, Rosen CJ.

J Am Geriatr Soc. 2006 May;54(5):782-9.

PMID:
16696744
11.

Efficacy of teriparatide in increasing bone mineral density in postmenopausal women with osteoporosis--an Indian experience.

Sethi BK, Chadha M, Modi KD, Kumar KM, Mehrotra R, Sriram U.

J Assoc Physicians India. 2008 Jun;56:418-24.

PMID:
18822620
12.

Vertebral fracture risk after once-weekly teriparatide injections: follow-up study of Teriparatide Once-Weekly Efficacy Research (TOWER) trial.

Sugimoto T, Shiraki M, Nakano T, Kishimoto H, Ito M, Fukunaga M, Hagino H, Sone T, Kuroda T, Nakamura T.

Curr Med Res Opin. 2013 Mar;29(3):195-203. doi: 10.1185/03007995.2012.761956. Epub 2013 Jan 17.

PMID:
23259702
13.

Change in lumbar spine BMD and vertebral fracture risk reduction in teriparatide-treated postmenopausal women with osteoporosis.

Chen P, Miller PD, Delmas PD, Misurski DA, Krege JH.

J Bone Miner Res. 2006 Nov;21(11):1785-90.

14.

Sequential treatment of severe postmenopausal osteoporosis after teriparatide: final results of the randomized, controlled European Study of Forsteo (EUROFORS).

Eastell R, Nickelsen T, Marin F, Barker C, Hadji P, Farrerons J, Audran M, Boonen S, Brixen K, Gomes JM, Obermayer-Pietsch B, Avramidis A, Sigurdsson G, Gl├╝er CC.

J Bone Miner Res. 2009 Apr;24(4):726-36. doi: 10.1359/jbmr.081215.

15.

Teriparatide: new preparation. Osteoporosis: less well evaluated than alendronic acid.

[No authors listed]

Prescrire Int. 2005 Feb;14(75):5-9.

PMID:
15747448
17.

Meta-analysis of walking for preservation of bone mineral density in postmenopausal women.

Martyn-St James M, Carroll S.

Bone. 2008 Sep;43(3):521-31. doi: 10.1016/j.bone.2008.05.012. Epub 2008 May 26.

PMID:
18602880
18.

Mixed-treatment comparison of anabolic (teriparatide and PTH 1-84) therapies in women with severe osteoporosis.

Migliore A, Broccoli S, Massafra U, Bizzi E, Frediani B.

Curr Med Res Opin. 2012 Mar;28(3):467-73. doi: 10.1185/03007995.2012.659724. Epub 2012 Feb 16.

PMID:
22256908
19.

Teriparatide and the risk of nonvertebral fractures in women with postmenopausal osteoporosis.

Krege JH, Wan X.

Bone. 2012 Jan;50(1):161-4. doi: 10.1016/j.bone.2011.10.018. Epub 2011 Oct 22.

PMID:
22036910
20.

Sustained nonvertebral fragility fracture risk reduction after discontinuation of teriparatide treatment.

Prince R, Sipos A, Hossain A, Syversen U, Ish-Shalom S, Marcinowska E, Halse J, Lindsay R, Dalsky GP, Mitlak BH.

J Bone Miner Res. 2005 Sep;20(9):1507-13. Epub 2005 May 2.

Supplemental Content

Support Center